Princeton Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Princeton Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,175	Closed	-$19K	–	238
2019 Q3	$19K	Hold	3,175	–	–	0.01%	193
2019 Q2	$38K	Sell	3,175 -13,812	-81%	-$149K	0.02%	164
2019 Q1	$205K	Sell	16,987 -900	-5%	-$13.3K	0.1%	91
2018 Q4	$224K	Buy	17,887 +832	+5%	+$11.5K	0.13%	81
2018 Q3	$253K	Buy	17,055 +473	+3%	+$7.44K	0.11%	88
2018 Q2	$279K	Hold	16,582	–	–	0.12%	81
2018 Q1	$380K	Buy	16,582 +700	+4%	+$15.6K	0.17%	71
2017 Q4	$411K	Buy	+15,882	New	+$320K	0.18%	68

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Princeton Capital Management's CNCE Position: Q4 2019 in Review

Princeton Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 3,175 shares — an estimated $19K sold.

Princeton Capital Management first reported a position in CNCE in Q4 2017 and held it in 8 quarters. The position peaked at $411K in Q4 2017. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

Princeton Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Princeton Capital Management sold 3,175 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $19K.
Princeton Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 8 quarters.
Princeton Capital Management's Concert Pharmaceuticals, Inc. position peaked at $411K in Q4 2017.
77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on Princeton Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.